.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Fish and Richardson
Covington
Cipla
Accenture
Johnson and Johnson
Julphar
Cerilliant
US Department of Justice

Generated: July 25, 2017

DrugPatentWatch Database Preview

Theravance Biopharma Company Profile

« Back to Dashboard

What is the competitive landscape for THERAVANCE BIOPHARMA, and what generic alternatives to THERAVANCE BIOPHARMA drugs are available?

THERAVANCE BIOPHARMA has one approved drug.

There are eleven US patents protecting THERAVANCE BIOPHARMA drugs.

There are one hundred and thirteen patent family members on THERAVANCE BIOPHARMA drugs in thirty-five countries.

Summary for Applicant: Theravance Biopharma

Patents:11
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Theravance Biopharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,887,976 Glycopeptide phosphonate derivatives► Subscribe
7,244,705Polyacid glycopeptide derivatives► Subscribe
7,074,760Polyacid glycopeptide derivatives► Subscribe
8,003,755Hydrochloride salts of a glycopeptide phosphonate derivative► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Theravance Biopharma Drugs

Country Document Number Estimated Expiration
Japan2008222718► Subscribe
CroatiaP20020888► Subscribe
New Zealand522279► Subscribe
Austria337334► Subscribe
Germany60122516► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Theravance Biopharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00033Denmark► Subscribe
7Finland► Subscribe
C0051France► SubscribePRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
00507Netherlands► SubscribePRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
2011100062Germany► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Medtronic
Fish and Richardson
Chubb
Cerilliant
Covington
QuintilesIMS
Chinese Patent Office
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot